Unexpected findings show that the body’s own immune system destroys retinal cells.
Glaucoma, a disease that afflicts nearly 70 million people worldwide, is something of a mystery despite its prevalence. Little is known about the origins of the disease, which damages the retina and optic nerve and can lead to blindness.
A new study from MIT and Massachusetts Eye and Ear has found that glaucoma may in fact be an autoimmune disorder. In a study of mice, the researchers showed that the body’s own T cells are responsible for the progressive retinal degeneration seen in glaucoma. Furthermore, these T cells appear to be primed to attack retinal neurons as the result of previous interactions with bacteria that normally live in our body.
The discovery suggests that it could be possible to develop new treatments for glaucoma by blocking this autoimmune activity, the researchers say.
“This opens a new approach to prevent and treat glaucoma,” says Jianzhu Chen, an MIT professor of biology, a member of MIT’s Koch Institute for Integrative Cancer Research, and one of the senior authors of the study, which appears in Nature Communications on Aug. 10.
Dong Feng Chen, an associate professor of ophthalmology at Harvard Medical School and the Schepens Eye Research Institute of Massachusetts Eye and Ear, is also a senior author of the study. The paper’s lead authors are Massachusetts Eye and Ear researchers Huihui Chen, Kin-Sang Cho, and T.H. Khanh Vu.
Genesis of glaucoma
One of the biggest risk factors for glaucoma is elevated pressure in the eye, which often occurs as people age and the ducts that allow fluid to drain from the eye become blocked. The disease often goes undetected at first; patients may not realize they have the disease until half of their retinal ganglion cells have been lost.
Most treatments focus on lowering pressure in the eye (also known as intraocular pressure). However, in many patients, the disease worsens even after intraocular pressure returns to normal. In studies in mice, Dong Feng Chen found the same effect.
“That led us to the thought that this pressure change must be triggering something progressive, and the first thing that came to mind is that it has to be an immune response,” she says.
To test that hypothesis, the researchers looked for immune cells in the retinas of these mice and found that indeed, T cells were there. This is unusual because T cells are normally blocked from entering the retina, by a tight layer of cells called the blood-retina barrier, to suppress inflammation of the eye. The researchers found that when intraocular pressure goes up, T cells are somehow able to get through this barrier and into the retina.
The Mass Eye and Ear team then enlisted Jianzhu Chen, an immunologist, to further investigate what role these T cells might be playing in glaucoma. The researchers generated high intraocular pressure in mice that lack T cells and found that while this pressure induced only a small amount of damage to the retina, the disease did not progress any further after eye pressure returned to normal.
Further studies revealed that the glaucoma-linked T cells target proteins called heat shock proteins, which help cells respond to stress or injury. Normally, T cells should not target proteins produced by the host, but the researchers suspected that these T cells had been previously exposed to bacterial heat shock proteins. Because heat shock proteins from different species are very similar, the resulting T cells can cross-react with mouse and human heat shock proteins.
To test this hypothesis, the team brought in James Fox, a professor in MIT’s Department of Biological Engineering and Division of Comparative Medicine, whose team maintains mice with no bacteria. The researchers found that when they tried to induce glaucoma in these germ-free mice, the mice did not develop the disease.
The researchers then turned to human patients with glaucoma and found that these patients had five times the normal level of T cells specific to heat shock proteins, suggesting that the same phenomenon may also contribute to the disease in humans. The researchers’ studies thus far suggest that the effect is not specific to a particular strain of bacteria; rather, exposure to a combination of bacteria can generate T cells that target heat shock proteins.
One question the researchers plan to study further is whether other components of the immune system may be involved in the autoimmune process that gives rise to glaucoma. They are also investigating the possibility that this phenomenon may underlie other neurodegenerative disorders, and looking for ways to treat such disorders by blocking the autoimmune response.
“What we learn from the eye can be applied to the brain diseases, and may eventually help develop new methods of treatment and diagnosis,” Dong Feng Chen says.
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- New glaucoma treatment eyed by UTHSC faculty member's startup OculoTherapyon November 30, 2021 at 10:12 am
OculoTherapy is developing a new therapeutic for glaucoma — the most common cause of irreversible blindness worldwide — with an eye drop that could target both factors of the disease that lead to ...
- Glaucoma, a leading cause of irreversible blindnesson November 30, 2021 at 7:30 am
Have you ever faced eye redness? Or have witnessed blurry or foggy vision? Or experiencing halos around lights? Or nausea and vomiting are very common for you. You may well be suffering from Glaucoma ...
- Glaucoma Treatment Market Regional Growth in North America, US, China, Europe, South Korea, Russia and More By Forecast to 2027on November 29, 2021 at 10:34 pm
Portland United States A new market research report by Big Market Research on Glaucoma Treatment Market reveals that the market is estimated to grow with a substantial growth rate from 2021 2026 This ...
- New Falck device provides several glaucoma diagnosticson November 29, 2021 at 7:58 am
The new FMAT1 measures tonometry, ophthalmodynamometry, tonography and ocular pulse amplitude, helping clinicians better manage glaucoma, J. James Thimons, OD, said at the American Academy of ...
- Open-Angle Glaucoma Therapeutics Market Share 2021 – Global Growth, Trends, Industry Analysis, Key Players and Forecast 2026on November 28, 2021 at 8:56 pm
Global Open-Angle Glaucoma Therapeutics Market Report provides region-wise analysis which is done in the report that ...
- Intraocular Filtration Devices Market Demand Is Driven By Increasing Patients Suffering From Glaucomaon November 28, 2021 at 8:00 pm
A newly compiled research report by Fact.MR offers valuable perspectives on Intraocular Filtration Devices market survey and detailed insights pertaining to its Sales growth prospects and outlook over ...
- Nicotinamide and pyruvate help improve vision in glaucoma patients: JAMAon November 28, 2021 at 7:30 pm
USA: A new study reveals that a combination of nicotinamide and pyruvate significantly improved visual function in the short term. The results confirm previous experimental research suggesting a role ...
- Winner of 2021 Dyson Award Goes to First Ever Device to Monitor Glaucoma Symptoms From Homeon November 28, 2021 at 8:43 am
HOPES, A device for pain-free, at-home eye pressure testing for glaucoma won the 2021 Dyson Award for breakthrough design.
- Closing the Gap in Glaucomaon November 21, 2021 at 4:00 pm
Until about a decade ago, glaucoma experts were in a quandary when it came to treating patients whose disease existed somewhere between mild and severe, says Jella An, M.D., the new chief of the ...
via Bing News